title: Partial response to bevacizumab of an extensive cutaneous angiosarcoma of the face.
authors.forename: A
authors.initials: A
authors.lastname: Rosen
authors.forename: S
authors.initials: S
authors.lastname: Thimon
authors.forename: D
authors.initials: D
authors.lastname: Ternant
authors.forename: M C
authors.initials: MC
authors.lastname: Machet
authors.forename: G
authors.initials: G
authors.lastname: Paintaud
authors.forename: L
authors.initials: L
authors.lastname: Machet
mesh_terms: D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005153:Facial Neoplasms / Q000188:drug therapy*; D005260:Female; D006394:Hemangiosarcoma / Q000188:drug therapy*; D006801:Humans; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab